MedTrace Logo

Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles

NCT01007851 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2009-11-04

No results posted yet for this study

Summary

GnRH agonist administration in the luteal phase was reported to beneficially affect clinical outcome of ICSI-ET cycles. This randomized controlled trial evaluates the effect of a single dose GnRH agonist administered in the luteal phase on the outcome of ICSI - ET cycles stimulated with the fixed GnRH antagonist protocol. Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol were included. In addition to routine luteal phase support with progesterone women were randomized to receive a single dose of GnRH agonist or placebo on the sixth day after ICSI.Ongoing pregnancy rate was the primary outcome measure.

Conditions

Interventions

DRUG

triptorelin acetate

single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer

DRUG

NaCl %0.9

0.1 ml sterile saline sc injection 3 days after embryo transfer

Sponsors & Collaborators

  • V.K.V. American Hospital, Istanbul

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2007-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01007851 on ClinicalTrials.gov